ID PPARG_RAT Reviewed; 505 AA. AC O88275; Q9QWG0; Q9R197; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 01-AUG-1999, sequence version 2. DT 27-MAR-2024, entry version 212. DE RecName: Full=Peroxisome proliferator-activated receptor gamma; DE Short=PPAR-gamma; DE AltName: Full=Nuclear receptor subfamily 1 group C member 3; GN Name=Pparg; Synonyms=Nr1c3; OS Rattus norvegicus (Rat). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; OC Murinae; Rattus. OX NCBI_TaxID=10116; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2). RC STRAIN=Sprague-Dawley; TISSUE=Brown adipose tissue; RX PubMed=10438514; DOI=10.1074/jbc.274.33.23368; RA Guardiola-Diaz H.M., Rehnmark S., Usuda N., Albrektsen T., Feltkamp D., RA Gustafsson J.-A., Alexson S.E.H.; RT "Rat peroxisome proliferator-activated receptors and brown adipose tissue RT function during cold acclimatization."; RL J. Biol. Chem. 274:23368-23377(1999). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC STRAIN=Sprague-Dawley; TISSUE=Adipose tissue; RA Tanaka T., Itoh H.; RT "Down-regulation of PPAR gammma."; RL Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Escher P.; RL Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Adipocyte; RA Miyakita A., Okuno S., Watanabe T.K., Oga K., Tsuji A., Hishigaki H., RA Suto T., Nakagawa K., Nakahara Y., Higashi K.; RT "Molecular cloning of rat PPAR-gamma gene."; RL Submitted (FEB-1998) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC STRAIN=Long Evans; RX PubMed=10797535; RX DOI=10.1002/(sici)1097-4547(20000501)60:3<328::aid-jnr7>3.0.co;2-5; RA Ershov A.V., Bazan N.G.; RT "Photoreceptor phagocytosis selectively activates PPARgamma expression in RT retinal pigment epithelial cells."; RL J. Neurosci. Res. 60:328-337(2000). RN [6] RP PHOSPHORYLATION. RX PubMed=8953045; DOI=10.1126/science.274.5295.2100; RA Hu E., Kim J.B., Sarraf P., Spiegelman B.M.; RT "Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of RT PPARgamma."; RL Science 274:2100-2103(1996). RN [7] RP PHOSPHORYLATION AT SER-112, AND MUTAGENESIS OF SER-112. RX PubMed=9030579; DOI=10.1074/jbc.272.8.5128; RA Adams M., Reginato M.J., Shao D., Lazar M.A., Chatterjee V.K.; RT "Transcriptional activation by peroxisome proliferator-activated receptor RT gamma is inhibited by phosphorylation at a consensus mitogen-activated RT protein kinase site."; RL J. Biol. Chem. 272:5128-5132(1997). RN [8] RP PHOSPHORYLATION. RX PubMed=8943212; DOI=10.1074/jbc.271.50.31771; RA Zhang B., Berger J., Zhou G., Elbrecht A., Biswas S., White-Carrington S., RA Szalkowski D., Moller D.E.; RT "Insulin- and mitogen-activated protein kinase-mediated phosphorylation and RT activation of peroxisome proliferator-activated receptor gamma."; RL J. Biol. Chem. 271:31771-31774(1996). CC -!- FUNCTION: Nuclear receptor that binds peroxisome proliferators such as CC hypolipidemic drugs and fatty acids. Once activated by a ligand, the CC nuclear receptor binds to DNA specific PPAR response elements (PPRE) CC and modulates the transcription of its target genes, such as acyl-CoA CC oxidase. It therefore controls the peroxisomal beta-oxidation pathway CC of fatty acids. Key regulator of adipocyte differentiation and glucose CC homeostasis. ARF6 acts as a key regulator of the tissue-specific CC adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut CC homeostasis by suppressing NF-kappa-B-mediated pro-inflammatory CC responses. Plays a role in the regulation of cardiovascular circadian CC rhythms by regulating the transcription of BMAL1 in the blood vessels. CC {ECO:0000250|UniProtKB:P37231, ECO:0000250|UniProtKB:P37238}. CC -!- ACTIVITY REGULATION: PDPK1 activates its transcriptional activity CC independently of its kinase activity. {ECO:0000250}. CC -!- SUBUNIT: Interacts with FOXO1 (acetylated form) (By similarity). CC Heterodimer with other nuclear receptors, such as RXRA. The heterodimer CC with the retinoic acid receptor RXRA is called adipocyte-specific CC transcription factor ARF6. Interacts with NCOA6 coactivator, leading to CC a strong increase in transcription of target genes. Interacts with CC coactivator PPARBP, leading to a mild increase in transcription of CC target genes. Interacts with NOCA7 in a ligand-inducible manner. CC Interacts with NCOA1 and NCOA2 LXXLL motifs. Interacts with ASXL1, CC ASXL2, DNTTIP2, FAM120B, MAP2K1/MEK1, NR0B2, PDPK1, PRDM16, PRMT2 and CC TGFB1I1. Interacts (when activated by agonist) with PPP5C. Interacts CC with HELZ2 and THRAP3; the interaction stimulates the transcriptional CC activity of PPARG. Interacts with PER2, the interaction is ligand CC dependent and blocks PPARG recruitment to target promoters. Interacts CC with NOCT. Interacts with ACTN4. Interacts (when in the liganded CC conformation) with GPS2 (By similarity). Interacts with CRY1 and CRY2 CC in a ligand-dependent manner (By similarity). In the absence of CC hormonal ligand, interacts with TACC1 (By similarity). CC {ECO:0000250|UniProtKB:P37231, ECO:0000250|UniProtKB:P37238}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00407}. CC Cytoplasm {ECO:0000250}. Note=Redistributed from the nucleus to the CC cytosol through a MAP2K1/MEK1-dependent manner. NOCT enhances its CC nuclear translocation (By similarity). {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Comment=Additional isoforms seem to exist.; CC Name=2; CC IsoId=O88275-1; Sequence=Displayed; CC Name=1; CC IsoId=O88275-2; Sequence=VSP_003649; CC -!- TISSUE SPECIFICITY: Highest expression in adipose tissue. CC -!- DOMAIN: The 9aaTAD motif is a transactivation domain present in a large CC number of yeast and animal transcription factors. CC {ECO:0000250|UniProtKB:P37231}. CC -!- PTM: Phosphorylated by MAPK. The phosphorylation inhibits PPAR gamma CC activity. {ECO:0000269|PubMed:8943212, ECO:0000269|PubMed:8953045, CC ECO:0000269|PubMed:9030579}. CC -!- PTM: O-GlcNAcylation at Thr-84 reduces transcriptional activity in CC adipocytes. {ECO:0000250|UniProtKB:P37238}. CC -!- PTM: Phosphorylated at basal conditions and dephosphorylated when CC treated with the ligand. May be dephosphorylated by PPP5C. The CC phosphorylated form may be inactive and dephosphorylation at induces CC adipogenic activity (By similarity). {ECO:0000250|UniProtKB:P37231}. CC -!- PTM: Ubiquitinated by E3 ubiquitin-protein ligase complex containing CC FBXO9; leading to proteasomal degradation (By similarity). CC Ubiquitinated at Lys-252 by TRIM55 leading to proteasomal degradation CC (By similarity). {ECO:0000250|UniProtKB:P37231, CC ECO:0000250|UniProtKB:P37238}. CC -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR1 CC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF156666; AAD40119.1; -; mRNA. DR EMBL; AF156665; AAD40118.1; -; mRNA. DR EMBL; AB019561; BAA36485.1; -; mRNA. DR EMBL; Y12882; CAA73382.2; -; mRNA. DR EMBL; AB011365; BAA32540.1; -; mRNA. DR EMBL; AF246457; AAF63385.1; -; mRNA. DR EMBL; AF246458; AAF63386.1; -; mRNA. DR RefSeq; NP_001138838.1; NM_001145366.1. [O88275-2] DR RefSeq; NP_001138839.1; NM_001145367.1. [O88275-2] DR RefSeq; NP_037256.1; NM_013124.3. [O88275-1] DR RefSeq; XP_006237071.1; XM_006237009.3. [O88275-2] DR AlphaFoldDB; O88275; -. DR BMRB; O88275; -. DR SMR; O88275; -. DR STRING; 10116.ENSRNOP00000012137; -. DR BindingDB; O88275; -. DR ChEMBL; CHEMBL4797; -. DR DrugCentral; O88275; -. DR GlyCosmos; O88275; 1 site, No reported glycans. DR GlyGen; O88275; 1 site. DR iPTMnet; O88275; -. DR PhosphoSitePlus; O88275; -. DR PaxDb; 10116-ENSRNOP00000012137; -. DR Ensembl; ENSRNOT00000012137.6; ENSRNOP00000012137.3; ENSRNOG00000008839.8. [O88275-1] DR Ensembl; ENSRNOT00000082969.2; ENSRNOP00000073235.1; ENSRNOG00000008839.8. [O88275-2] DR Ensembl; ENSRNOT00055015492; ENSRNOP00055012408; ENSRNOG00055009152. [O88275-1] DR Ensembl; ENSRNOT00060044788; ENSRNOP00060037139; ENSRNOG00060025849. [O88275-1] DR Ensembl; ENSRNOT00065050179; ENSRNOP00065041216; ENSRNOG00065029023. [O88275-1] DR GeneID; 25664; -. DR KEGG; rno:25664; -. DR UCSC; RGD:3371; rat. [O88275-1] DR AGR; RGD:3371; -. DR CTD; 5468; -. DR RGD; 3371; Pparg. DR eggNOG; KOG3575; Eukaryota. DR GeneTree; ENSGT00940000158273; -. DR InParanoid; O88275; -. DR OMA; AIDYKYD; -. DR OrthoDB; 3475284at2759; -. DR PhylomeDB; O88275; -. DR TreeFam; TF316304; -. DR Reactome; R-RNO-381340; Transcriptional regulation of white adipocyte differentiation. DR Reactome; R-RNO-383280; Nuclear Receptor transcription pathway. DR PRO; PR:O88275; -. DR Proteomes; UP000002494; Chromosome 4. DR Bgee; ENSRNOG00000008839; Expressed in duodenum and 18 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; ISO:RGD. DR GO; GO:0005829; C:cytosol; ISO:RGD. DR GO; GO:0005654; C:nucleoplasm; IEA:Ensembl. DR GO; GO:0005634; C:nucleus; ISO:RGD. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:RGD. DR GO; GO:0043235; C:receptor complex; ISO:RGD. DR GO; GO:0090575; C:RNA polymerase II transcription regulator complex; ISO:RGD. DR GO; GO:0106068; C:SUMO ligase complex; ISO:RGD. DR GO; GO:0051393; F:alpha-actinin binding; ISO:RGD. DR GO; GO:0050544; F:arachidonic acid binding; ISO:RGD. DR GO; GO:0003682; F:chromatin binding; ISS:UniProtKB. DR GO; GO:0003677; F:DNA binding; IDA:RGD. DR GO; GO:0050692; F:DNA binding domain binding; ISO:RGD. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; ISO:RGD. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:BHF-UCL. DR GO; GO:0140297; F:DNA-binding transcription factor binding; ISO:RGD. DR GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IBA:GO_Central. DR GO; GO:0003690; F:double-stranded DNA binding; ISO:RGD. DR GO; GO:0070888; F:E-box binding; ISS:UniProtKB. DR GO; GO:0019899; F:enzyme binding; ISO:RGD. DR GO; GO:0042802; F:identical protein binding; ISO:RGD. DR GO; GO:0050693; F:LBD domain binding; ISO:RGD. DR GO; GO:0030331; F:nuclear estrogen receptor binding; IPI:RGD. DR GO; GO:0004879; F:nuclear receptor activity; ISS:UniProtKB. DR GO; GO:0030374; F:nuclear receptor coactivator activity; ISO:RGD. DR GO; GO:0046965; F:nuclear retinoid X receptor binding; ISO:RGD. DR GO; GO:0003676; F:nucleic acid binding; ISO:RGD. DR GO; GO:0042277; F:peptide binding; ISO:RGD. DR GO; GO:1990841; F:promoter-specific chromatin binding; ISO:RGD. DR GO; GO:0019903; F:protein phosphatase binding; IDA:RGD. DR GO; GO:0043621; F:protein self-association; ISO:RGD. DR GO; GO:0070412; F:R-SMAD binding; ISO:RGD. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISO:RGD. DR GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; ISO:RGD. DR GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; ISO:RGD. DR GO; GO:0043565; F:sequence-specific DNA binding; ISO:RGD. DR GO; GO:0097677; F:STAT family protein binding; ISO:RGD. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:BHF-UCL. DR GO; GO:0001223; F:transcription coactivator binding; IPI:RGD. DR GO; GO:0001221; F:transcription coregulator binding; ISO:RGD. DR GO; GO:0008270; F:zinc ion binding; ISO:RGD. DR GO; GO:0031100; P:animal organ regeneration; IEP:RGD. DR GO; GO:0030509; P:BMP signaling pathway; ISO:RGD. DR GO; GO:0050873; P:brown fat cell differentiation; ISO:RGD. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0045165; P:cell fate commitment; ISO:RGD. DR GO; GO:0048469; P:cell maturation; ISO:RGD. DR GO; GO:0008283; P:cell population proliferation; ISO:RGD. DR GO; GO:0071455; P:cellular response to hyperoxia; IEP:RGD. DR GO; GO:0071456; P:cellular response to hypoxia; IDA:BHF-UCL. DR GO; GO:0032869; P:cellular response to insulin stimulus; ISS:UniProtKB. DR GO; GO:0071285; P:cellular response to lithium ion; ISO:RGD. DR GO; GO:0071404; P:cellular response to low-density lipoprotein particle stimulus; ISO:RGD. DR GO; GO:0071407; P:cellular response to organic cyclic compound; ISO:RGD. DR GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; ISO:RGD. DR GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEP:RGD. DR GO; GO:0071379; P:cellular response to prostaglandin stimulus; IEP:RGD. DR GO; GO:0071300; P:cellular response to retinoic acid; IEP:RGD. DR GO; GO:0071306; P:cellular response to vitamin E; IEP:RGD. DR GO; GO:0106106; P:cold-induced thermogenesis; ISO:RGD. DR GO; GO:0002024; P:diet induced thermogenesis; ISO:RGD. DR GO; GO:0030855; P:epithelial cell differentiation; ISO:RGD. DR GO; GO:0050673; P:epithelial cell proliferation; ISO:RGD. DR GO; GO:0045444; P:fat cell differentiation; ISO:RGD. DR GO; GO:0006631; P:fatty acid metabolic process; IBA:GO_Central. DR GO; GO:0019395; P:fatty acid oxidation; IMP:RGD. DR GO; GO:0042593; P:glucose homeostasis; ISO:RGD. DR GO; GO:0007507; P:heart development; IEP:RGD. DR GO; GO:0009755; P:hormone-mediated signaling pathway; IBA:GO_Central. DR GO; GO:0042953; P:lipoprotein transport; ISO:RGD. DR GO; GO:0015909; P:long-chain fatty acid transport; ISO:RGD. DR GO; GO:0010742; P:macrophage derived foam cell differentiation; ISS:UniProtKB. DR GO; GO:0030224; P:monocyte differentiation; ISO:RGD. DR GO; GO:0042789; P:mRNA transcription by RNA polymerase II; ISO:RGD. DR GO; GO:0002674; P:negative regulation of acute inflammatory response; IMP:RGD. DR GO; GO:0016525; P:negative regulation of angiogenesis; ISO:RGD. DR GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; ISO:RGD. DR GO; GO:0030514; P:negative regulation of BMP signaling pathway; ISO:RGD. DR GO; GO:1903243; P:negative regulation of cardiac muscle hypertrophy in response to stress; IDA:BHF-UCL. DR GO; GO:0030308; P:negative regulation of cell growth; IMP:RGD. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:RGD. DR GO; GO:1900077; P:negative regulation of cellular response to insulin stimulus; ISO:RGD. DR GO; GO:1903845; P:negative regulation of cellular response to transforming growth factor beta stimulus; ISO:RGD. DR GO; GO:0010887; P:negative regulation of cholesterol storage; ISO:RGD. DR GO; GO:0032966; P:negative regulation of collagen biosynthetic process; IMP:RGD. DR GO; GO:1904597; P:negative regulation of connective tissue replacement involved in inflammatory response wound healing; IDA:BHF-UCL. DR GO; GO:0001818; P:negative regulation of cytokine production; ISO:RGD. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; ISO:RGD. DR GO; GO:0050680; P:negative regulation of epithelial cell proliferation; ISO:RGD. DR GO; GO:1901202; P:negative regulation of extracellular matrix assembly; ISO:RGD. DR GO; GO:0010629; P:negative regulation of gene expression; IGI:BHF-UCL. DR GO; GO:0050728; P:negative regulation of inflammatory response; IBA:GO_Central. DR GO; GO:0010888; P:negative regulation of lipid storage; IDA:BHF-UCL. DR GO; GO:0010745; P:negative regulation of macrophage derived foam cell differentiation; ISO:RGD. DR GO; GO:1903979; P:negative regulation of microglial cell activation; ISO:RGD. DR GO; GO:1902894; P:negative regulation of miRNA transcription; ISO:RGD. DR GO; GO:0090258; P:negative regulation of mitochondrial fission; ISO:RGD. DR GO; GO:0150079; P:negative regulation of neuroinflammatory response; ISO:RGD. DR GO; GO:0045668; P:negative regulation of osteoblast differentiation; ISO:RGD. DR GO; GO:2000230; P:negative regulation of pancreatic stellate cell proliferation; IMP:RGD. DR GO; GO:0090278; P:negative regulation of peptide hormone secretion; ISO:RGD. DR GO; GO:1904893; P:negative regulation of receptor signaling pathway via STAT; ISO:RGD. DR GO; GO:0010891; P:negative regulation of sequestering of triglyceride; ISO:RGD. DR GO; GO:0060392; P:negative regulation of SMAD protein signal transduction; ISO:RGD. DR GO; GO:0014912; P:negative regulation of smooth muscle cell migration; ISO:RGD. DR GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IGI:BHF-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISO:RGD. DR GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; ISO:RGD. DR GO; GO:0060336; P:negative regulation of type II interferon-mediated signaling pathway; ISO:RGD. DR GO; GO:1904706; P:negative regulation of vascular associated smooth muscle cell proliferation; ISO:RGD. DR GO; GO:1905563; P:negative regulation of vascular endothelial cell proliferation; ISO:RGD. DR GO; GO:0035357; P:peroxisome proliferator activated receptor signaling pathway; ISO:RGD. DR GO; GO:0001890; P:placenta development; ISO:RGD. DR GO; GO:0070165; P:positive regulation of adiponectin secretion; IDA:BHF-UCL. DR GO; GO:1904179; P:positive regulation of adipose tissue development; ISO:RGD. DR GO; GO:0043065; P:positive regulation of apoptotic process; IMP:RGD. DR GO; GO:0010875; P:positive regulation of cholesterol efflux; ISO:RGD. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:UniProtKB. DR GO; GO:0045600; P:positive regulation of fat cell differentiation; IMP:ARUK-UCL. DR GO; GO:0045923; P:positive regulation of fatty acid metabolic process; IBA:GO_Central. DR GO; GO:0046321; P:positive regulation of fatty acid oxidation; IMP:RGD. DR GO; GO:0010628; P:positive regulation of gene expression; ISO:RGD. DR GO; GO:1902895; P:positive regulation of miRNA transcription; ISO:RGD. DR GO; GO:0048714; P:positive regulation of oligodendrocyte differentiation; IMP:RGD. DR GO; GO:0060100; P:positive regulation of phagocytosis, engulfment; IMP:RGD. DR GO; GO:0060391; P:positive regulation of SMAD protein signal transduction; ISO:RGD. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR GO; GO:1905461; P:positive regulation of vascular associated smooth muscle cell apoptotic process; ISO:RGD. DR GO; GO:0008217; P:regulation of blood pressure; ISO:RGD. DR GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB. DR GO; GO:0006355; P:regulation of DNA-templated transcription; ISO:RGD. DR GO; GO:0045598; P:regulation of fat cell differentiation; IDA:RGD. DR GO; GO:0010468; P:regulation of gene expression; ISO:RGD. DR GO; GO:0019216; P:regulation of lipid metabolic process; IMP:RGD. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IMP:RGD. DR GO; GO:0031000; P:response to caffeine; IEP:RGD. DR GO; GO:0002021; P:response to dietary excess; ISO:RGD. DR GO; GO:0043627; P:response to estrogen; IEP:RGD. DR GO; GO:0032094; P:response to food; ISO:RGD. DR GO; GO:0035902; P:response to immobilization stress; IEP:RGD. DR GO; GO:0009416; P:response to light stimulus; ISO:RGD. DR GO; GO:0033993; P:response to lipid; IEP:RGD. DR GO; GO:0009612; P:response to mechanical stimulus; IEP:RGD. DR GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD. DR GO; GO:0010033; P:response to organic substance; IEP:RGD. DR GO; GO:0042594; P:response to starvation; IEP:RGD. DR GO; GO:0033189; P:response to vitamin A; IEP:RGD. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD. DR GO; GO:0048384; P:retinoic acid receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW. DR GO; GO:0007165; P:signal transduction; ISO:RGD. DR GO; GO:0050872; P:white fat cell differentiation; ISO:RGD. DR GO; GO:0002246; P:wound healing involved in inflammatory response; ISO:RGD. DR CDD; cd06965; NR_DBD_Ppar; 1. DR CDD; cd06932; NR_LBD_PPAR; 1. DR Gene3D; 3.30.50.10; Erythroid Transcription Factor GATA-1, subunit A; 1. DR Gene3D; 1.10.565.10; Retinoid X Receptor; 1. DR InterPro; IPR003074; 1Cnucl_rcpt. DR InterPro; IPR035500; NHR-like_dom_sf. DR InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd. DR InterPro; IPR001723; Nuclear_hrmn_rcpt. DR InterPro; IPR003077; PPAR-gamma. DR InterPro; IPR022590; PPARgamma_N. DR InterPro; IPR001628; Znf_hrmn_rcpt. DR InterPro; IPR013088; Znf_NHR/GATA. DR PANTHER; PTHR24082; NUCLEAR HORMONE RECEPTOR; 1. DR PANTHER; PTHR24082:SF488; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA; 1. DR Pfam; PF00104; Hormone_recep; 1. DR Pfam; PF12577; PPARgamma_N; 1. DR Pfam; PF00105; zf-C4; 1. DR PRINTS; PR01288; PROXISOMEPAR. DR PRINTS; PR01291; PROXISOMPAGR. DR PRINTS; PR00398; STRDHORMONER. DR PRINTS; PR00047; STROIDFINGER. DR SMART; SM00430; HOLI; 1. DR SMART; SM00399; ZnF_C4; 1. DR SUPFAM; SSF57716; Glucocorticoid receptor-like (DNA-binding domain); 1. DR SUPFAM; SSF48508; Nuclear receptor ligand-binding domain; 1. DR PROSITE; PS51843; NR_LBD; 1. DR PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1. DR PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1. DR Genevisible; O88275; RN. PE 1: Evidence at protein level; KW Activator; Alternative splicing; Biological rhythms; Cytoplasm; KW DNA-binding; Glycoprotein; Isopeptide bond; Metal-binding; Nucleus; KW Phosphoprotein; Receptor; Reference proteome; Transcription; KW Transcription regulation; Ubl conjugation; Zinc; Zinc-finger. FT CHAIN 1..505 FT /note="Peroxisome proliferator-activated receptor gamma" FT /id="PRO_0000053497" FT DOMAIN 238..503 FT /note="NR LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01189" FT DNA_BIND 136..210 FT /note="Nuclear receptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00407" FT ZN_FING 139..159 FT /note="NR C4-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00407" FT ZN_FING 176..198 FT /note="NR C4-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00407" FT REGION 205..280 FT /note="Interaction with FAM120B" FT /evidence="ECO:0000250" FT MOTIF 495..503 FT /note="9aaTAD" FT /evidence="ECO:0000250|UniProtKB:P37231" FT MOD_RES 112 FT /note="Phosphoserine; by MAPK" FT /evidence="ECO:0000269|PubMed:9030579" FT CARBOHYD 84 FT /note="O-linked (GlcNAc) threonine" FT /evidence="ECO:0000250" FT CROSSLNK 252 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000250|UniProtKB:P37231" FT VAR_SEQ 1..30 FT /note="Missing (in isoform 1)" FT /evidence="ECO:0000303|PubMed:10438514, FT ECO:0000303|PubMed:10797535, ECO:0000303|Ref.4" FT /id="VSP_003649" FT MUTAGEN 112 FT /note="S->A: Increases adipogenic activity." FT /evidence="ECO:0000269|PubMed:9030579" FT CONFLICT 111 FT /note="A -> R (in Ref. 3; CAA73382)" FT /evidence="ECO:0000305" SQ SEQUENCE 505 AA; 57567 MW; F16E5CAB122EBB32 CRC64; MGETLGDPPV DPEHGAFADA LPMSTSQEIT MVDTEMPFWP TNFGISSVDL SVMDDHSHSF DIKPFTTVDF SSISAPHYED IPFTRADPMV ADYKYDLKLQ EYQSAIKVEP ASPPYYSEKT QLYNRPHEEP SNSLMAIECR VCGDKASGFH YGVHACEGCK GFFRRTIRLK LIYDRCDLNC RIHKKSRNKC QYCRFQKCLA VGMSHNAIRF GRMPQAEKEK LLAEISSDID QLNPESADLR ALAKHLYDSY IKSFPLTKAK ARAILTGKTT DKSPFVIYDM NSLMMGEDKI KFKHITPLQE QSKEVAIRIF QGCQFRSVEA VQEITEYAKN IPGFINLDLN DQVTLLKYGV HEIIYTMLAS LMNKDGVLIS EGQGFMTREF LKSLRKPFGD FMEPKFEFAV KFNALELDDS DLAIFIAVII LSGDRPGLLN VKPIEDIQDN LLQALELQLK LNHPESSQLF AKVLQKMTDL RQIVTEHVQL LHVIKKTETD MSLHPLLQEI YKDLY //